They were great results with MS for 1102 with 70 patients - yet why was it dropped by big pharma and impossible for them to find anybody else to license it for the last 10 years ?
That's always the big question mark - it's not like other companies and big pharma have not known about it.
Hopefully pivoting to a new target and DMD will change it ?
DMD Phase 2 Results in Q4 = Potential 5000% Gem, page-137
-
- There are more pages in this discussion • 166 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 10.5¢ | $35.58K | 335.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 375558 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 41673 | 2 |
View Market Depth
| Last trade - 11.01am 18/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |